SCI时时刷

search
+
Identifying Hereditary Leiomyomatosis and Renal Cell Cancer through Unobtrusive Cutaneous Nodules: A Clinical Report
1. Hansen AW, Chayed Z, Pallesen K, Vasilescu IC, Bygum A. Hereditary leiomyomatosis and renal cell cancer. Acta D...
Identifying Hereditary Leiomyomatosis and Renal Cell Cancer through Unobtrusive Cutaneous Nodules
Emilija Šeštokaitė Clinic of Infectious Diseases and Dermatovenerology, Vilnius Uni...
Relationship between ZHX2 Expression and VHL Gene Alterationin VHL-associated and Sporadic Hemangioblastomas of the Central Nervous System
1. Tse JY, Wong JH, Lo KW, Poon WS, Huang DP, Ng HK. Molecular genetic analysis of the von Hippel–Lindau disease t...
Surveillance in Children and Adolescents with von Hippel-Lindau (VHL)-Related Pheochromocytomas and Paragangliomas: A Survey of MET and Freiburg-VHL Registries in Germany
1. Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Can...
Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel–Lindau?
Aaron R. Hochberg Department of Urology, Sidney Kimmel Medical College, Thomas Jeff...
Surveillance in Children and Adolescents with von Hippel-Lindau (VHL)-Related Pheochromocytomas and Paragangliomas
Fruzsina Kotsis Department of Medicine IV – Nephrology and Primary Care, University...
Primary Nonseminomatous Germ Cell Tumor of Kidney: An Uncommon Renal Neoplasm
1. Garnick MB, Canellos GP, Richie JP. Treatment and surgical staging of testicular and primary extragonadal germ cell ca...
Avoidable Benign Kidney Tumor Resections—Data from a Tertiary Care Cancer Institute
Keywords Benign kidney tumor, Kidney Cancer, Renal Tumor, Nephrectomy, Overtreatment References 1. Shin T, Dudda...
Primary Nonseminomatous Germ Cell Tumor of Kidney
Sonu Kumar Plash Department of Urology, All India Institute of Medical Sciences (AIIMS) Bhopal, Saket Nagar, Habib Ganj,...
Approach to Diagnosis of TFE3-rearranged Renal Cell Carcinoma in a Limited Resource Setting: A Case Report
1. Argani P, Martignoni G, Mehra R, Yu W. TFE3-rearranged renal cell carcinomas. In: Moch H, editors. Urinary and Male Ge...
Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation (osteosarcomatous and chondrosarcomatous differentiation) - A case report and comprehensive review
Meenakshi Rao Department of Pathology & Lab Medicine, All India Institute of Medical Sciences, Jodhpur, Rajasthan, I...
Epithelial Predominant Wilms Tumor in an Adult Patient: Case Report and Literature Review
1. Spreafico F, Ferrari A, Mascarin M, Collini P, Morosi C, Biasoni D, et al. Wilms tumor, medulloblastoma, and rhabdomyo...
Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials
1. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus ...
Clinical trials for immunotherapy-based regimens in metastatic renal cell carcinoma (mRCC) have extensive inclusion and exclusion criteria. We investigated the clinical outcomes in a real-world cohort of patients who would not have met the criteria for inclusion in front-line mRCC trials. Patients treated with ipilimumab/nivolumab and axitinib/pembrolizumab for front-line mRCC were identified and divided into clinical trial eligi-ble (CTE) and clinical trial ineligible (CTI) cohorts based on key inclusion or exclusion criteria from their respective Phase-3 registration trials. Clinical outcomes were compared in CTE and CTI cohorts. A total of 62 patients treated with axitinib/pembrolizumab and 103 treated with ipilimumab/nivolumab were identified. The International Metastatic RCC Database Consortium (IMDC) criteria were similar across CTE and CTI patients in axitinib/pembrolizumab and ipilimumab/nivolumab cohorts. In the axitinib/pembrolizumab cohort (n = 62), 24 (39%) patients were CTI. The major reasons for
1. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus ...
An Uncommon Case of Sinonasal Adenoid Cystic Carcinoma Metastatic to the Kidney Treated with Metastasectomy
1. Piazza P, Oliveira Paludo A de, Puliatti S, Rosiello G, Farinha R, Amato M, et al. Bilateral kidney metastases from ad...
Clinical trials for immunotherapy-based regimens in metastatic renal cell carcinoma (mRCC) have extensive inclusion and exclusion criteria. We investigated the clinical outcomes in a real-world cohort of patients who would not have met the criteria for inclusion in front-line mRCC trials. Patients treated with ipilimumab/nivolumab and axitinib/pembrolizumab for front-line mRCC were identified and divided into clinical trial eligi-ble (CTE) and clinical trial ineligible (CTI) cohorts based on key inclusion or exclusion criteria from their respective Phase-3 registration trials. Clinical outcomes were compared in CTE and CTI cohorts. A total of 62 patients treated with axitinib/pembrolizumab and 103 treated with ipilimumab/nivolumab were identified. The International Metastatic RCC Database Consortium (IMDC) criteria were similar across CTE and CTI patients in axitinib/pembrolizumab and ipilimumab/nivolumab cohorts. In the axitinib/pembrolizumab cohort (n = 62), 24 (39%) patients were CTI. The major reasons for
1. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus ...
Approach to Diagnosis of TFE3-rearranged Renal Cell Carcinoma in a Limited Resource Setting
Allison Kaye L. Pagarigan, MD Department of Pathology and Laboratory Medicine, National Kidney and Transplant Institute,...
Epithelial Predominant Wilms Tumor in an Adult Patient
References1. Spreafico F, Ferrari A, Mascarin M, Collini P, Morosi C, Biasoni D, et al. Wilms tumor, medulloblastoma, and...
Comparison of Trifecta and Pentafecta Outcomes across 3 Surgical Modalities of Partial Nephrectomy (PN) – Open, Lap, and Robotic
1. Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al. Chronic kidney disease after nephrectomy in patient...
Clinical T1a Renal Cell Carcinoma with Solitary Diaphragmatic Metastasis in a Patient with von Hippel-Lindau Disease
Tadataka Hirai Department of Radiology, Okayama University Hospital, Okayama, Japan Mayu Uka Department of Radiology, ...
Clinical, Genomic, and Transcriptomic Characteristics of Patients with Metastatic Renal Cell Carcinoma Who Developed Thromboembolic Events
1. Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer pa...
Nephrectomies in Saudi Arabia: A Comprehensive Analysis of Outcomes from a High-Volume Minimally Invasive Surgery Center
1. Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal function after nephron-sparing surgery versus rad...
Portal Venous Thrombosis after Percutaneous Cryoablation for Renal Cell Carcinoma
Takahiro Kawabata Department of Radiology, Okayama University Hospital, Okayama, Japan Toshihiro Iguchi Department of ...
Preoperative Super-Selective Embolization versus “On-Clamp” Laparoscopic Partial Nephrectomy for T1 Renal Tumors— A Prospective Randomized Study
1. Butler BP, Novick AC, Miller DP, Campbell SA, Licht MR. Management of small unilateral renal cell carcinomas: Radical ...
Active Surveillance in Metastatic Renal Cell Carcinoma
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/...
Preoperative Super-Selective Embolization versus “On-Clamp” Laparoscopic Partial Nephrectomy for T1 Renal Tumors
Vivek Kumar Singh Department of Urology and renal transplantation, Gauhati medical college, Guwahati, Assam, India Deba...
Prevalence of neurological symptoms and imaging findings in von Hippel-Lindau patients referred to Rasool Akram Hospital, 2018-2021
Seyed Hamidreza Javadi Department of Neurology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran S...
Native Kidney Renal Cell Carcinoma in Renal Allograft Transplant Patients –Our Experience
Pavan Survase Department of Urology, Muljibhai Patel Urological Hospital, Nadiad, Gujarat, India Shashank Agrawal Depa...
Impressive and Prolonged Response with Lenvatinib in a Highly Pretreated Patient with Metastatic Clear Cell Renal Cancer: A Case Report
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN es...
Impressive and Prolonged Response with Lenvatinib in a Highly Pretreated Patient with Metastatic Clear Cell Renal Cancer
Keywords case report, lenvatinib, renal cell carcinoma, tyrosine kinase inhibitor, VHL mutation References 1. Su...
阅读更多
format_indent_increase